X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2471) 2471
Publication (118) 118
Newsletter (73) 73
Book Review (14) 14
Newspaper Article (10) 10
Magazine Article (9) 9
Book Chapter (5) 5
Trade Publication Article (4) 4
Web Resource (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telmisartan (2406) 2406
index medicus (996) 996
humans (948) 948
male (768) 768
hypertension (731) 731
female (517) 517
hypertension - drug therapy (488) 488
pharmacology & pharmacy (471) 471
animals (414) 414
benzimidazoles - therapeutic use (412) 412
middle aged (412) 412
benzoates - therapeutic use (401) 401
peripheral vascular disease (380) 380
aged (350) 350
benzimidazoles - pharmacology (333) 333
benzoates - pharmacology (325) 325
blood pressure - drug effects (310) 310
angiotensin ii type 1 receptor blockers - therapeutic use (301) 301
angiotensin (279) 279
antihypertensive agents - therapeutic use (261) 261
treatment outcome (254) 254
rats (250) 250
blood-pressure (245) 245
losartan (234) 234
valsartan (227) 227
blood pressure (225) 225
ramipril (223) 223
angiotensin ii type 1 receptor blockers - pharmacology (221) 221
risk factors (212) 212
adult (209) 209
benzimidazoles - administration & dosage (209) 209
hydrochlorothiazide (203) 203
research (202) 202
benzoates - administration & dosage (201) 201
cardiac & cardiovascular systems (199) 199
drug therapy, combination (194) 194
angiotensin-converting enzyme inhibitors - therapeutic use (190) 190
drug therapy (184) 184
hypertension - physiopathology (181) 181
oxidative stress (177) 177
diabetes (160) 160
risk (158) 158
metabolic syndrome (155) 155
analysis (148) 148
mice (148) 148
medicine, general & internal (146) 146
prevention (142) 142
dosage and administration (139) 139
ppar-gamma (139) 139
health aspects (138) 138
angiotensin ii type 1 receptor blockers - administration & dosage (135) 135
amlodipine (132) 132
angiotensin ii (132) 132
mortality (131) 131
renin-angiotensin system (130) 130
disease (127) 127
expression (127) 127
angiotensin-ii (126) 126
inflammation (125) 125
cardiovascular events (121) 121
insulin resistance (120) 120
medicine, research & experimental (120) 120
dose-response relationship, drug (119) 119
antihypertensive agents - administration & dosage (117) 117
double-blind (117) 117
care and treatment (116) 116
hypertension - complications (115) 115
benzimidazoles - adverse effects (113) 113
prospective studies (110) 110
benzoates - adverse effects (109) 109
angiotensin ii receptor blocker (108) 108
double-blind method (107) 107
hypertensive patients (107) 107
irbesartan (105) 105
endocrinology & metabolism (104) 104
candesartan (103) 103
efficacy (103) 103
antihypertensive agents - pharmacology (102) 102
time factors (99) 99
disease models, animal (98) 98
internal medicine (98) 98
angiotensin receptor blockers (97) 97
high-risk (95) 95
insulin-resistance (94) 94
renin-angiotensin system - drug effects (93) 93
obesity (90) 90
medicine & public health (89) 89
heart-failure (88) 88
pharmacokinetics (87) 87
apoptosis (86) 86
stroke (86) 86
antihypertensive agents - adverse effects (85) 85
cardiovascular disease (85) 85
myocardial-infarction (84) 84
nephropathy (84) 84
medicine (81) 81
tetrazoles - therapeutic use (81) 81
cardiovascular diseases (80) 80
angiotensin ii type 1 receptor blockers - adverse effects (79) 79
diabetes mellitus, type 2 - complications (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2443) 2443
German (28) 28
Russian (22) 22
Spanish (16) 16
Japanese (14) 14
Chinese (9) 9
Polish (8) 8
French (7) 7
Korean (7) 7
Czech (6) 6
Hungarian (3) 3
Portuguese (2) 2
Turkish (2) 2
Indonesian (1) 1
Italian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicology, ISSN 0300-483X, 12/2019, Volume 428, p. 152310
Pregabalin (PRG) is highly effective in the treatment of epilepsy, neuropathic pain and anxiety disorders. Despite its potential benefits, PRG administration... 
Heart failure | Pregabalin | Captopril | Telmisartan
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 05/2019
Journal Article
Pharmacological Research, ISSN 1043-6618, 11/2009, Volume 60, Issue 5, pp. 373 - 381
Doxorubicin (Dox) is a potent anticancer agent; its clinical use is limited for its marked cardiotoxicity and nephrotoxicity. The present study investigated... 
Doxorubicin-nephrotoxicity | Doxorubicin-cardiotoxicity | Telmisartan versus captopril
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 2013, Volume 172, Issue 1, pp. 86 - 95
The purpose of the present study was to evaluate the effect of Telmisartan (Tel) and Losartan (Los) on nanoparticle intratumoral distribution and anticancer... 
Intratumoral | Nanotherapeutics | Collagen | Distribution | Inhalation | Telmisartan
Journal Article
International Journal of Research in Pharmaceutical Sciences, 10/2018, Volume 9, Issue 4, pp. 1368 - 1373
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 01/2020, Volume 171, p. 113674
Telmisartan ameliorates inflammation in various brain disorders through angiotensin II type 1 receptor (AT1) blockade and peroxisome proliferator-activated... 
Amyloid-β oligomers | PTEN | Inflammation | PPARγ | Telmisartan
Journal Article
Life Sciences, ISSN 0024-3205, 11/2019, Volume 237, p. 116890
Telmisartan (TEL), an angiotensin II type I receptor blocker and PPARγ partial agonist, has been used for to treat hypertension. It is known that PPARγ... 
Hypertension | Bone | Ovariectomy | PPARγ | Telmisartan
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10085, pp. 2226 - 2237
Summary Background Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure... 
Internal Medicine | MORTALITY | MEDICINE, GENERAL & INTERNAL | ONGOING TELMISARTAN | METAANALYSIS | RAMIPRIL | RATIONALE | DISEASE | TARGETS | COMBINATION | HYPERTENSIVE PATIENTS | ANTIHYPERTENSIVE TREATMENT | Benzoates - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Randomized Controlled Trials as Topic - methods | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Hospitalization - statistics & numerical data | Hypertension - drug therapy | Male | Multicenter Studies as Topic | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypotension - mortality | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Cardiovascular Diseases - physiopathology | Antihypertensive Agents - therapeutic use | Hypotension - chemically induced | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Telmisartan | Hypotension - complications | Aged | Blood pressure | Hospitals | Research institutes | Germany | Myocardial infarction | Heart | Intervention | Syngeneic grafts | Funding | Medical services | Clinical trials | Cardiovascular disease | Blood | Optimization | Risk factors | Clinical outcomes | Incidence | Recruitment | Peptidyl-dipeptidase A | Risk assessment | Failure analysis | Pretreatment | Heart diseases | Hypertension | Cerebral infarction | Stroke | Risk groups | Adjustment | Categories | Mortality | Regression analysis | Patients | Variance analysis | Oral cavity | Inhibitors | Converting | Angiotensin | Death | Fatalities | Infarction | Cardiovascular diseases | Health risk assessment
Journal Article
Journal of Hypertension, ISSN 0263-6352, 10/2018, Volume 36 Suppl 3, pp. e294 - e294
OBJECTIVES:To investigate the effect of telmisartan combined with rosuvastatin on the brain matter lesions (WMLs) in elderly patients with hypertension.... 
Hypertension | Aged patients | Usage | Care and treatment | Health aspects | Telmisartan
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 09/2017, Volume 491, Issue 4, pp. 903 - 911
Telmisartan, an angiotensin II type 1 receptor blocker (ARB), attenuates hyperglycemia-aggravated vascular inflammation by decreasing IκB kinase β (IKKβ)... 
GSK3β | Hyperglycemia | VCAM-1 | Vascular inflammation | Telmisartan
Journal Article
Journal of Molecular Liquids, ISSN 0167-7322, 12/2019, Volume 295, p. 111719
In this study, the mole-fraction solubility data for telmisartan in dichloromethane + primary alcohol (methanol, ethanol, -propanol or -butanol) mixtures were... 
Solvent synergy | Supercritical antisolvent technique | Nanoparticle | Solubility | Telmisartan
Journal Article
Medičnì Perspektivi, ISSN 2307-0404, 09/2016, Volume 21, Issue 3, pp. 26 - 29
In 41 patients with essential hy­pertension I and II degrees telmisartan influence on parameters of intimate heodynamics and functional condition of myocardium... 
telmisartan | essential hypertension | hemodynamics
Journal Article
Neuropharmacology, ISSN 0028-3908, 04/2014, Volume 79, pp. 249 - 261
Sartans (Angiotensin II AT Receptor Blockers, ARBs) are powerful neuroprotective agents in vivo and protect against IL-1β neurotoxicity in vitro. The purpose... 
Angiotensin II AT | Neuroprotection | Glutamate neurotoxicity | Receptor Blockers | PPARγ | Apoptosis | Telmisartan
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.